L3VLUP
ProSign in

ELAN · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ELANJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ELAN
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterELANJNJ
Q3 20206 holders, $2.9bn30 holders, $26.2bn
Q4 202016 holders, $4.1bn32 holders, $26.6bn
Q1 202112 holders, $4.0bn31 holders, $25.3bn
Q2 202114 holders, $4.6bn37 holders, $25.6bn
Q3 202110 holders, $4.0bn40 holders, $24.1bn
Q4 202113 holders, $3.8bn33 holders, $25.2bn
Q1 202211 holders, $3.1bn35 holders, $28.2bn
Q2 202211 holders, $2.4bn33 holders, $26.9bn
Q3 202215 holders, $1.9bn36 holders, $25.4bn
Q4 202215 holders, $1.7bn35 holders, $27.6bn
Q1 202312 holders, $1.2bn42 holders, $24.5bn
Q2 202313 holders, $1.6bn38 holders, $25.0bn
Q3 202312 holders, $1.7bn37 holders, $18.9bn
Q4 20239 holders, $1.9bn31 holders, $19.0bn
Q1 202410 holders, $2.3bn32 holders, $19.7bn
Q2 20249 holders, $2.1bn35 holders, $20.4bn
Q3 20247 holders, $1.5bn28 holders, $22.3bn
Q4 20245 holders, $1.5bn37 holders, $20.4bn
Q1 20256 holders, $1.5bn32 holders, $20.5bn
Q2 20259 holders, $2.5bn31 holders, $18.4bn
Q3 202512 holders, $3.4bn32 holders, $23.7bn
Q4 20259 holders, $3.3bn29 holders, $27.8bn
Q1 20265 holders, $3.0bn34 holders, $35.6bn
Q2 202610 holders, $3.6bn33 holders, $39.1bn
ELAN

Elanco Animal Health Inc

Holders
9
Reported value
$2.1bn
Buyers
6
Sellers
4

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ELAN (3)

Balyasny Asset Management LLC, Davidson Kempner Capital Management LP, Holocene Advisors LP

Only JNJ (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, MFS Investment Management, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Two Sigma Investments LP, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →